NSCLC Spectrum Pharmaceuticals poziotinib
Spectrum expands Phase ll trial of poziotinib for NSCLC
Spectrum Pharmaceuticals has expanded its Phase ll clinical trial of poziotinib for the treatment of non-small cell lung cancer (NSCLC)…
Spectrum expands Phase ll trial of poziotinib for NSCLC
Spectrum Pharmaceuticals has expanded its Phase ll clinical trial of poziotinib for non-small cell lung cancer (NSCLC) by adding two…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox